Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer

被引：7

作者：

Huang, Audris ^{[1
]}

Jayaraman, Lata ^{[1
]}

Fura, Aberra ^{[1
]}

Vite, Gregory D. ^{[1
]}

Trainor, George L. ^{[1
]}

Gottardis, Marco M. ^{[1
]}

Spires, Thomas E. ^{[1
]}

Spires, Vanessa M. ^{[1
]}

Rizzo, Cheryl A. ^{[1
]}

Obermeier, Mary T. ^{[1
]}

Elzinga, Paul A. ^{[1
]}

Todderud, Gordon ^{[1
]}

Fan, Yi ^{[1
]}

Newitt, John A. ^{[1
]}

Beyer, Sophie M. ^{[1
]}

Zhu, Yongxin ^{[1
]}

Warrack, Bethanne M. ^{[1
]}

Goodenough, Angela K. ^{[1
]}

Tebben, Andrew J. ^{[1
]}

Doweyko, Arthur M. ^{[1
]}

Gold, David L. ^{[1
]}

Balog, Aaron ^{[1
]}

机构：

[1] Bristol Myers Squibb Res & Dev, Princeton, NJ 08543 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2016年 / 7卷 / 01期

关键词：

Prostate cancer; CYP17A1; benzimidazoles; lyase; CYP11B1; CYP21A2; cortisol; CASTRATION-RESISTANT; 17,20-LYASE INHIBITOR; ORTERONEL TAK-700; N-ARYLATION; ABIRATERONE;

D O I：

10.1021/acsmedchemlett.5b00310

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Efforts to identify a potent, reversible, non steroidal CYP17A1 lyase inhibitor with good selectivity over CYP17A1 hydroxylase and CYPs 11B1 and 21A2 for the treatment of castration-resistant prostate cancer (CRPC) culminated in the discovery of BMS-351 (compound 18), a pyridyl biaryl benzimidazole with an excellent in vivo profile. Biological evaluation of BMS-351 at a dose of 1.5 mg in castrated cynomolgus monkeys revealed a remarkable reduction in testosterone levels with minimal glucocorticoid and mineralcorticoid perturbation. Based on a favorable profile, BMS-351 was selected as a candidate for further preclinical evaluation.

引用

页码：40 / 45

页数：6

共 50 条

[1] The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer
Darne, Chetan Padmakar
Velaparthi, Upender
Saulnier, Mark
Frennesson, David
Liu, Peiying
Huang, Audris
Tokarski, John
Fura, Aberra
Spires, Thomas
Newitt, John
Spires, Vanessa M.
Obermeier, Mary T.
Elzinga, Paul A.
Gottardis, Marco M.
Jayaraman, Lata
Vite, Gregory D.
Balog, Aaron
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 75
[2] Structure-based discovery of selective CYP17A1 inhibitors for Castration-resistant prostate cancer treatment
Omoboyowa, Damilola A.
Balogun, Toheeb A.
Saibu, Oluwatosin A.
Chukwudozie, Onyeka S.
Alausa, Abdullahi
Olubode, Samuel O.
Aborode, Abdullahi T.
Batiha, Gaber E.
Bodun, Damilola S.
Musa, Sekinat O.
BIOLOGY METHODS & PROTOCOLS, 2022, 7 (01):
[3] CYP17A1 expression in prostate cancer
Giatromanolaki, A.
Fasoulaki, V.
Kalamida, D.
Sivridis, E.
Koukourakis, M.
VIRCHOWS ARCHIV, 2018, 473 : S255 - S256
[4] Friedelin, a novel inhibitor of CYP17A1 in prostate cancer from Cassia tora
Joshi, Bhrugesh Pravinchandra
Bhandare, Vishwambhar Vishnu
Vankawala, Mahima
Patel, Prittesh
Patel, Rajesh
Vyas, Bhavin
Krishnamurty, Ramar
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (19): : 9695 - 9720
[5] Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Toren, Paul J.
Kim, Soojin
Pham, Steven
Mangalji, Azzra
Adomat, Hans
Guns, Emma S. Tomlinson
Zoubeidi, Amina
Moore, William
Gleave, Martin E.
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (01) : 59 - 69
[6] Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition
Krug, Sebastian J.
Hu, Qingzhong
Hartmann, Rolf W.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2013, 134 : 75 - 79
[7] CYP17A1 inhibitors in castration-resistant prostate cancer
Gomez, Lissette
Kovac, Jason R.
Lamb, Dolores J.
STEROIDS, 2015, 95 : 80 - 87
[8] Anticancer activity of the selective CYP17A1 inhibitor, VT-464, in preclinical models of castrate-resistant prostate cancer
Toren, Paul
Pham, Steven
Kim, Soojin
Adomat, Hans
Zoubeidi, Amina
Moore, William R.
Gleave, Martin Edwin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[9] Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer
Wang, Ao
Luo, Xianggang
Meng, Xin
Lu, Zhengyu
Chen, Kaixian
Yang, Yushe
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (14) : 9972 - 9991
[10] The Discovery of Potent and Selective Inhibitors of CYP17 Lyase
Balog, A.
Jayaraman, L.
Fura, A.
Vite, G. D.
Gottardis, M.
Huang, A.
Newitt, J. A.
Spires, T. E.
Obermeier, M. T.
Beyer, S. M.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 38 - 39

← 1 2 3 4 5 →